CVS Halts Sales of OTC Zantac
Tests have found low levels of the nitrosamine impurity NDMA in some ranitidine products
MONDAY, Sept. 30, 2019 (HealthDay News) -- CVS is the latest drugstore chain to stop selling over-the-counter Zantac (ranitidine), as well as the store's own generic version of the heartburn medicine, because of contamination with a known carcinogen.
The U.S. Food and Drug Administration warned consumers earlier in September not to use prescription and over-the-counter versions of Zantac, the Associated Press reported.
CVS says it will take back any Zantac products and refund the money. In the meantime, CVS continues to sell other heartburn medications.
Preliminary tests have found low levels of the nitrosamine impurity N-nitrosodimethylamine (NDMA) in some ranitidine products. NDMA has been found in many brands of blood pressure and heart failure medicines during the past year and has led to recalls.